You searched for irritable bowel syndrome - MPR
Skip to navigation Skip to main content

Your search for irritable bowel syndrome returned 142 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for irritable bowel syndrome returned 142 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Vibegron Under Review for Overactive Bladder Treatment

Publish Date
The FDA has accepted for review the New Drug Application for vibegron (Urovant Sciences) for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Drugs in the Pipeline

NDA Submitted for Vibegron for Overactive Bladder Treatment

Publish Date
Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The NDA submission includes data from an extensive clinical development program involving over 4000 patients with…
Clinical Charts

Irritable Bowel Syndrome Evaluation

Publish Date
Irritable Bowel Syndrome (IBS) evaluation chart based on Manning Criteria and Rome III Diagnostic Criteria.
News

FDA Approves First-in-Class Treatment for IBS-C

Publish Date
The Food and Drug Administration (FDA) has approved Ibsrela (tenapanor; Ardelyx) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Ibsrela is a locally-acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium.…